Leerink Partnrs Comments on Ironwood Pharmaceuticals, Inc.’s FY2024 Earnings (NASDAQ:IRWD)

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Equities research analysts at Leerink Partnrs issued their FY2024 earnings per share (EPS) estimates for Ironwood Pharmaceuticals in a research note issued to investors on Monday, September 9th. Leerink Partnrs analyst F. Khurshid anticipates that the biotechnology company will post earnings of $0.10 per share for the year. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.28 per share. Leerink Partnrs also issued estimates for Ironwood Pharmaceuticals’ FY2026 earnings at $0.42 EPS.

Several other analysts also recently issued reports on IRWD. Wells Fargo & Company cut their target price on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating on the stock in a research note on Friday, August 9th. StockNews.com raised Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, July 16th. Capital One Financial cut Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $12.00 to $4.00 in a research note on Thursday, August 8th. Leerink Partners began coverage on shares of Ironwood Pharmaceuticals in a research report on Monday. They issued a “market perform” rating and a $5.00 price target for the company. Finally, Craig Hallum lowered their price objective on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $13.57.

Ironwood Pharmaceuticals Trading Up 6.6 %

Shares of IRWD opened at $4.35 on Tuesday. The business’s 50-day moving average price is $5.62 and its 200 day moving average price is $6.97. The stock has a market capitalization of $694.87 million, a P/E ratio of -0.64 and a beta of 0.49. Ironwood Pharmaceuticals has a 1-year low of $3.79 and a 1-year high of $15.70.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Old West Investment Management LLC boosted its stake in Ironwood Pharmaceuticals by 1.4% during the 4th quarter. Old West Investment Management LLC now owns 56,921 shares of the biotechnology company’s stock valued at $651,000 after purchasing an additional 761 shares during the period. Texas Permanent School Fund Corp boosted its holdings in Ironwood Pharmaceuticals by 1.3% during the first quarter. Texas Permanent School Fund Corp now owns 120,245 shares of the biotechnology company’s stock valued at $1,047,000 after purchasing an additional 1,557 shares in the last quarter. CWM LLC grew its position in Ironwood Pharmaceuticals by 55.1% during the 2nd quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 2,345 shares during the last quarter. Louisiana State Employees Retirement System raised its stake in shares of Ironwood Pharmaceuticals by 3.5% in the second quarter. Louisiana State Employees Retirement System now owns 70,400 shares of the biotechnology company’s stock worth $459,000 after acquiring an additional 2,400 shares during the last quarter. Finally, SummerHaven Investment Management LLC lifted its position in shares of Ironwood Pharmaceuticals by 3.6% during the second quarter. SummerHaven Investment Management LLC now owns 72,030 shares of the biotechnology company’s stock worth $470,000 after purchasing an additional 2,491 shares in the last quarter.

Insiders Place Their Bets

In other news, insider Minardo John sold 9,910 shares of the company’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $4.27, for a total transaction of $42,315.70. Following the completion of the sale, the insider now owns 284,661 shares in the company, valued at approximately $1,215,502.47. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 12.90% of the company’s stock.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.